Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. (ARTV): 6 pipeline candidates · 4 upcoming catalysts · ~12 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
12.1 months
D/E 0.21
Lead: Phase 1/Phase 2
6 candidates
4 upcoming, next in ~1591d
3 buys · 5 sells (180d)
A transparent, data-derived signal for Artiva Biotherapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$483.0M
Cash
$21.4M
Quarterly Burn
$20.9M
Runway
12.1 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| ab-101 | Phase 1/Phase 2 |
| allogeneic nk cells | Phase 2 |
| allonk | Phase 2 |
| bendamustine | Phase 1/Phase 2 |
| fludarabine | Phase 1/Phase 2 |
| interleukin-2 | Phase 1/Phase 2 |
Upcoming Catalysts (4)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
35
Total value held
$77.9M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 9,853,302 | $63.5M |
| franklin resources inc | 520,327 | $3.4M |
| vanguard capital management llc | 415,372 | $2.7M |
| blackrock, inc. | 213,388 | $1.4M |
| wellington management group llp | 194,108 | $1.3M |
| millennium management llc | 123,270 | $794K |
| two sigma investments, lp | 115,041 | $741K |
| geode capital management, llc | 101,695 | $655K |
| alyeska investment group, l.p. | 100,000 | $644K |
| renaissance technologies llc | 80,038 | $515K |
Showing top 10 of 35 institutional holders of Artiva Biotherapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Artiva Biotherapeutics, Inc.'s pipeline?
Artiva Biotherapeutics, Inc. (ARTV) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Artiva Biotherapeutics, Inc.'s lead drug candidate?
Artiva Biotherapeutics, Inc.'s most advanced tracked candidate is ab-101 (Phase 1/Phase 2) for Non Hodgkin Lymphoma.
What is Artiva Biotherapeutics, Inc.'s next catalyst?
Artiva Biotherapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: TREANDA" — expected October 26, 2030.
What is Artiva Biotherapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Artiva Biotherapeutics, Inc. has approximately 12.1 months of cash runway.
What is Artiva Biotherapeutics, Inc.'s market capitalization?
Artiva Biotherapeutics, Inc.'s market capitalization is approximately $483.0M.
Get the full picture on Artiva Biotherapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.